Clinical Trial Update: Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya [Phase 2]

View source ↗

Summary

A Phase 2 feasibility trial in Kenya evaluating intravaginal artesunate as an adjuvant treatment for HPV-related cervical precancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Human Immunodeficiency Virus Infection
• Human Papillomavirus Infection

Drugs mentioned

• Artesunate (artesunate)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Human Immunodeficiency Virus, Human Papillomavirus | Phase 2 | Status: COMPLETED